Shares Of Editas Medicine, Inc. (EDIT) bought By NIKOLIC BORIS

Faith Castro
August 12, 2017

Going out even further, the 200-Day Simple Moving Average is recorded 20.33% away from the current share price. Chardan maintained its investment rating on the stock at buy. TD Asset Management Inc. now owns 33,770 shares of the company's stock worth $754,000 after buying an additional 2,800 shares in the last quarter. As per WSJ analytic report, EDIT for the Q3 this year, the current consensus earnings per share trend estimates was $-0.53, while for one month ago estimates was $-0.60. The insider now holds 7.79 million shares of Editas Medicine, Inc. Finally, Driehaus Capital Management LLC increased its stake in Editas Medicine by 169.8% in the first quarter. They issued a "hold" rating and a $17.00 price target on the stock.

On the other hand Editas Medicine Cmn (NASDAQ:EDIT) has Relative Strength Index (RSI 14) of 65.92 along with Average True Range (ATR 14) of 1.17.

On average, analysts expect that Editas Medicine will report full-year sales of $2.88 million for the current year, with estimates ranging from $9.82 million to $29.93 million. The company's quarterly revenue was down 8.8% on a year-over-year basis. (NASDAQ:EDIT) is performing. Editas Medicine, Inc. has had 3 insider trades in the last 3 months, including 2 open market buys and 1 sells. Zacks Investment Research raised Editas Medicine from a "hold" rating to a "buy" rating and set a $19.00 price target for the company in a report on Wednesday, July 12th.

COPYRIGHT VIOLATION NOTICE: This article was published by Markets Daily and is owned by of Markets Daily. Revenue for the quarter also killed consensus, coming in at $3.1 Million, compared to the consensus of 2.4 Million.

On 3/15/2017 Alexandra Glucksmann, COO, sold 1,000 with an average share price of $26.41 per share and the total transaction amounting to $26,410.00. The company now has a consensus rating of "Buy" and an average target price of $26.03.

Several other hedge funds have also recently added to or reduced their stakes in the stock. It has a market cap of $823.9 Million. Bank of America Corp DE now owns 5,936 shares of the company's stock valued at $133,000 after buying an additional 2,489 shares during the last quarter. Trading volume for Editas Medicine, Inc. was 1,854K by the end of trading on Friday. The value of the total investment in Editas Medicine, Inc. went from $92,000 to $322,000 a change of 250.0% since the last quarter. The fund owned 9,101 shares of the company's stock after buying an additional 9,000 shares during the period. Nisa Investment Advisors LLC purchased a new stake in shares of Editas Medicine during the second quarter worth approximately $1,322,000. The stock had a trading volume of 501,864 shares. During the same quarter previous year, the firm posted ($0.54) earnings per share. UBS Group AG increased its stake in shares of Editas Medicine by 747.7% in the first quarter. They set a "market perform" rating for the company. The firm's revenue for the quarter was down 8.8% compared to the same quarter a year ago.

More news: Retirement Systems of Alabama Raises Stake in Dick's Sporting Goods Inc (DKS)

A number of key analysts, polled by FactSet, shared their views about the current stock momentum.

COPYRIGHT VIOLATION WARNING: This report was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. and global copyright and trademark law. The correct version of this article can be accessed at

Kevin Bitterman, Director reported the sale of 1,000,000 shares of EDIT stock.

According to Editas Medicine, Inc.'s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 67.06%.

The short interest to Editas Medicine Incorporated's float is 30.64%. Following the purchase, the director now owns 35,000 shares of the company's stock, valued at approximately $492,450. The disclosure for this purchase can be found here. The Company is involved in treating patients with genetically defined diseases by correcting their disease-causing genes.

Taking a broader look at the analyst consensus, according to 5 analysts Editas Medicine Cmn (NASDAQ:EDIT)'s price will reach at $35.2 during 52 weeks. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).

Other reports by LeisureTravelAid

Discuss This Article